– up to 18 months after the last mezagitamab dose.1The results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston.

IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.3By depleting cells that produce an abnormal protein called Gd-IgA1 implicated in the pathogenesis, mezagitamab targets early steps in the process leading to disease in IgA nephropathy.

“Mezagitamab targeted the underlying immune mechanisms of IgA nephropathy, with data showing that kidney function remained stable in patients after the last dose of treatment,” said Prof. Jonathan Barratt, M.D., Ph.D., principal investigator for the Phase 1b study and the presenting author. “This is especiall
=*=*=*=*=*=
当前为第2/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页